ClinicalTrials.gg
CompletedNCT03047460Updated Mar 6, 2019

Feasibility and Reliability of Multimodal Evoked Potentials in an International Multicenter Setting

An observational study in Multiple Sclerosis, sponsored by Clinique Neuro-Outaouais. Completed at 1 site in Canada. Open to participants aged 18 Years to 58 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-03-06.

Sponsored by Clinique Neuro-Outaouais · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
14
Ages
18 Years to 58 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 257 studies in Multiple Sclerosis with a site in Canada — 25 open to participants now, 43 under way, 12 of them phase 3. Multiple Sclerosis · Canada.

Enrollment
38th of 42
14 · median 172
Started
2016
with 9 others
Observational
42 of 257
2 open now
Registered
152nd of 257
by date
Lead sponsor
6 of 257
Clinique Neuro-Outaouais

Among the 257 studies in Multiple Sclerosis with a site in Canada, this one is the 38th largest by enrollment of the 42 observational ones that give a count, is one of 10 that started in 2016, is one of 42 observational ones, and was the 152nd registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

25 of the 257 studies in Multiple Sclerosis with a site in Canada are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 18 Years to 58 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 257 studies in Multiple Sclerosis with a site in Canada, or all of them as a file.
02

Study summary

Study Objectives and Endpoints:

Objective:

The primary objective of the study is to evaluate the feasibility and test-retest reliability of MEP's and (SSEP's) in a multicenter clinical trial in healthy subjects and subjects with MS.

Endpoints:

The primary reliability endpoint will be the intraclass correlation coefficient (ICC) of the following evoked potential parameters

Read the detailed description

The establishment of a biomarker(s) that can predict a clinical response to therapy over the course of a 1-2 year clinical trial is critical for the expeditious development of treatments for Multiple Sclerosis (MS). Identification of this biomarker would enable shorter and smaller clinical trials resulting in the faster development of much needed treatments for MS, specifically neuro-reparative therapies. The etiology of disease progression is conduction block, demyelination and axonal degeneration. Evoked potentials provide a direct assessment of the underlying etiologies of disease progression in MS. They are a functional assessment of multiple pathways, including visual, motor and sensory, evaluating the integrity of myelin and axons.

The variability of motor evoked potentials (MEP) measures has limited multimodal evoked potential (mmEP) use in international, multicenter clinical trials. MEP evaluation does significantly contribute to the predictive value of mmEP's. Recent advances in technology and establishment of standardized protocols for MEP reduces the variability associated with this procedure. The objective of this study is to evaluate the reliability and feasibility of MEP and SSEP in an international, multicenter trial so that mmEP can be further evaluated as a biomarker for disease progression. The rationale for this study is to explore the feasibility and reliability of MEP's and somatosensory evoked potentials (SSEP's) in a multicenter clinical trial for potential use as a biomarker that can predict clinical progression/improvement in international clinical trials evaluating remyelinating therapies.

Study Objectives and Endpoints:

Objective:

The primary objective of the study is to evaluate the feasibility and test-retest reliability of MEP's and (SSEP's) in a multicenter clinical trial in healthy subjects and subjects with MS.

Endpoints:

The primary reliability endpoint will be the intraclass correlation coefficient (ICC) of the following evoked potential parameters

Motor Evoked parameters that will be measured:

  • MEP latency
  • Central motor conduction time (CMCT) root latency methods
  • MEP amplitude
  • MEP amplitude to compound motor amplitude ratio (MEP-M ratio) for the right and left abductor digiti minimi (ADM) and the right and left tibialis anterior (TA)
  • Somatosensory evoked potential parameters will include Evoked potential latencies for both upper and lower limbs bilaterally.

Study Design:

This multinational, multicenter study will be conducted in healthy adult volunteers and MS patients to establish the feasibility and reliability of mmEP's. A total of 40 subjects, 10 (5 healthy and 5 MS) from each of the 4 sites will be enrolled.

The study will consist of two visits, 1-30 days apart, during which subjects will be screened to confirm eligibility and will complete all specified study assessments.

Study Locations:

Canada, Germany, Switzerland and Italy, with 1 site in each country.

Number of Planned Subjects:

A minimum of 40 subjects are planned for this study. Subjects who withdraw from the study prior to completion of the second visit may be replaced at the discretion of the investigator.

Study Population:

This study will be conducted in subjects 25 to 58 years of age, inclusive, who are either healthy volunteers (HV) or have been diagnosed with clinically definite MS who have a detectable lesion by MEP or SSEP.

Study Groups:

Two groups, healthy volunteers and clinically definite MS will be included.

Duration of Study Participation:

Study duration for each subject will be two visits, the second visit schedule >24 hours-30 days from the first visit

Criteria for Evaluation:

Key Study Assessments:

Electrophysiological. MEP's and SSEPs will be measured in both upper and lower limbs bilaterally. All studies will be read locally and reviewed by a blinded reader at another center. The ICC of every measured evoked potential parameter will be determined on both the central and local reads.

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

Keywords

  • motor evoked potential
  • somatosensory evoked potentials
  • biomarker
04

Who can participate

Ages eligible
18 Years to 58 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Healthy volunteers and MS patients aged 18 to 58 that have no other neurological comorbities that could affect evoked potential responses

Eligibility criteria

Inclusion Criteria:

  • To be eligible to participate in this study, candidates must meet the following eligibility criteria at Screening, or at the time point specified in the individual eligibility criterion listed (HV cohort):

    1. Ability to understand the purpose and risks of the study and provide signed and dated and authorization to use protected health information (PHI) in accordance with national and local subject privacy regulations.
    2. Aged 18 to 58 years old, inclusive, at the time of informed consent.
    3. Have no significant health issues, ie neuropathy or other demyelinating disorder that can affect testing.

Inclusion Criteria (MS Cohort)

To be eligible to be included in this cohort, candidates must meet the following additional eligibility criteria at Screening:

  1. Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (PHI) in accordance with national and local subject privacy regulations.
  2. Aged 18 to 58 years old, inclusive, at the time of informed consent.
  3. Diagnosis of MS (all types) with an expanded disability status scale (EDSS) 0.0 to 6.5.
  4. Have measurable responses on both MEP and SSEP in at least one upper and one lower limb. The MEP and SSEP responses do not need to be in the same limb
  5. Have no comorbid condition (ie neuropathy) that could affect testing.

Exclusion Criteria:

  • Candidates will be excluded from study entry if any of the following exclusion criteria exist at screening or at any time during the study.

    1. Inability to comply with study requirements.
    2. Unspecified reasons that, in the opinion of the Investigator, make the subject unsuitable for enrollment.
    3. Any diseases (e.g., non-MS demyelinating diseases), with the exception of diagnosis MS for the MS Cohort, that in the opinion of the Investigator, could influence evoked potential results ( including but not limited to medullary trauma, morbid obesity, limb amputation, diabetes, other polyneuropathy).
    4. MS relapse within 3 months of either sessions.
    5. Initiation of treatment or dose adjustment within 1 month of either sessions with Fampyra, Tegretol, Baclofen, Zanaflex
    6. Febrile illness within 3 days of either sessions.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
14 participants (actual)
Patient registry
No

Groups and cohorts

  • healthy

    healthy volunteers, 18 to 58 years old, with no neurological disease that could affect evoked potential responses Intervention: multimodal evoked potentials

    Other: multimodal evoked potentials

  • multiple sclerosis

    All types of Multiple sclerosis patients: * Aged 18 to 58 years old, inclusive, at the time of informed consent. * Expanded Disability Status Scale (EDSS) 0.0 to 6.5. * Have measurable responses on both MEP and SSEP in at least one upper and one lower limb. The MEP and SSEP responses do not need to be in the same limb * Have no comorbid condition (ie neuropathy) that could affect testing. Intervention: multimodal evoked potentials

    Other: multimodal evoked potentials

Interventions

  • Othermultimodal evoked potentials
06

What researchers measure

Primary outcomes

  1. Intraclass correlation coefficient (ICC) of the multi modal evoked potential parameters in order to determine the validity of the compound measures

    multi modal evoked potential will include: * MEP latency (msec) * Central motor conduction time (CMCT) using root latency methods (msec) * MEP amplitude (mvolt) and MEP/CMAP amplitude ratio (%)

    Time frame: obtained between two assessments done more than 24 hrs but less than 1 month apart

07

Study locations

1 site
  • Clinique Neuro-Outaouais
    Gatineau, Quebec J9J 0A5, Canada
08

References and documents

Individual participant data

Plan to share: Yes — the data will pooled with 3 other centers to augment the power of the study

Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code

Time frame: for the duration of the study and completion of the analyses

Access criteria: all PI's at each center will have access to the data

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2016 to primary completion in Jan 2018, 21 months.

Of 336 non-industry observational studies under Multiple Sclerosis, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 81. This study's 21 months is below that.

Counting every sponsor, half of 427 studies reached it within 41 months; a quarter within 15 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2016
First posted
Feb 9, 2017
StartActual
Apr 2016
Primary completionActual
Jan 2018
CompletionActual
Jan 2018
Last update
Mar 6, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03047460
Lead sponsor
Clinique Neuro-Outaouais
Responsible party
Dr. Francois Jacques (neurologist, Clinique Neuro-Outaouais) — Principal investigator
First posted
Feb 9, 2017
Start date
Apr 2016
Primary completion
Jan 2018
Completion
Jan 2018
Last update
Mar 6, 2019

Study contacts

François Jacques, MD
principal investigator · Clinique Neuro-Outaouais

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion